NMDA Enhancer for the Treatment of Mild Alzheimer's Disease
Status:
Completed
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
NMDA neurotransmission plays an important role in learning and memory. NMDA receptors (NMDAR)
were found to decrease in the frontal lobe and hippocampus of Alzheimer's disease (AD). This
study is a randomized, double-blind, placebo controlled drug trial for testing the efficacy
of NMDAR-enhancer. All subjects will be allocated randomly to 4 groups: (1) DAOI-A group; (2)
DAOI-B group; (3) DAOI-C group; (4) placebo group. The study period is 24 weeks. The
investigators hypothesize that DAOI may yield better efficacy than placebo for cognitive
function in patients with AD.